1.125USD-6.25%Mkt Cap: 62.79M USDP/E: —Last update: 2026-05-26
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap62.79M USD
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.50M USD
Revenue/Share—
Last Price1.125 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS70465T1079
Valuation
P/E (Trailing)—
P/E (Forward)-2.49
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B6.86
EPS (TTM)-0.66
EPS (Forward)-0.47
52W Range
0.507044% of range1.915
52W High1.915 USD
52W Low0.5070 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-372.85%
ROA-113.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.75M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity1.83
Current Ratio—
Quick Ratio—
Book Value/Sh0.1690 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 18, 2019
Splits
Last Split1:20
Split DateMar 18, 2019
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)7.500 USD
Target Range3.000 USD – 15.00 USD
# Analysts3
Ownership
Shares Out.55.82M
Float51.57M
Insiders1.51%
Institutions9.16%
Short Interest
Short Ratio1.4d
Short % Float3.16%
Short % Out.3.06%
Shares Short1.71M
Short (prev mo.)2.05M
Technical
SMA 500.9553 (+17.8%)
SMA 2000.9409 (+19.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.10M
Avg Vol (10d)1.28M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—